These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11534539)

  • 1. Risk factors for tardive dyskinesia in a large population of youths and adults.
    Wszola BA; Newell KM; Sprague RL
    Exp Clin Psychopharmacol; 2001 Aug; 9(3):285-96. PubMed ID: 11534539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.
    Morgenstern H; Glazer WM
    Arch Gen Psychiatry; 1993 Sep; 50(9):723-33. PubMed ID: 8102845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tardive dyskinesia in neuroleptic medicated mentally handicapped subjects.
    Rao JM; Cowie VA; Mathew B
    Acta Psychiatr Scand; 1987 Nov; 76(5):507-13. PubMed ID: 2893512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study.
    Ganzini L; Heintz RT; Hoffman WF; Casey DE
    Arch Gen Psychiatry; 1991 Mar; 48(3):259-63. PubMed ID: 1671743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients.
    Richardson MA; Haugland G; Craig TJ
    Am J Psychiatry; 1991 Oct; 148(10):1322-8. PubMed ID: 1680296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adolescents on neuroleptic medication: is this population at risk for tardive dyskinesia?
    McDermid SA; Hood J; Bockus S; D'Alessandro E
    Can J Psychiatry; 1998 Aug; 43(6):629-31. PubMed ID: 9729692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tardive dyskinesia and intellectual disability: an examination of demographics and topography in adults with dual diagnosis and atypical antipsychotic use.
    Fodstad JC; Bamburg JW; Matson JL; Mahan S; Hess JA; Neal D; Holloway J
    Res Dev Disabil; 2010; 31(3):750-9. PubMed ID: 20207106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979.
    Kane JM; Smith JM
    Arch Gen Psychiatry; 1982 Apr; 39(4):473-81. PubMed ID: 6121548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients.
    Go CL; Rosales RL; Caraos RJ; Fernandez HH
    Parkinsonism Relat Disord; 2009 Nov; 15(9):655-9. PubMed ID: 19346155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.
    Jeste DV; Caligiuri MP; Paulsen JS; Heaton RK; Lacro JP; Harris MJ; Bailey A; Fell RL; McAdams LA
    Arch Gen Psychiatry; 1995 Sep; 52(9):756-65. PubMed ID: 7654127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tardive dyskinesia: prevalence, incidence, and risk factors.
    Kane JM; Woerner M; Lieberman J
    Psychopharmacology Suppl; 1985; 2():72-8. PubMed ID: 2860662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent tardive dyskinesia: demographic and pharmacological risk factors.
    Muscettola G; Pampallona S; Barbato G; Casiello M; Bollini P
    Acta Psychiatr Scand; 1993 Jan; 87(1):29-36. PubMed ID: 8093821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of atypical versus typical antipsychotics on tardive dyskinesia: a naturalistic study.
    de Leon J
    Eur Arch Psychiatry Clin Neurosci; 2007 Apr; 257(3):169-72. PubMed ID: 17149539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    McGrath JJ; Soares KV
    Cochrane Database Syst Rev; 2000; (2):CD000459. PubMed ID: 10796546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tardive dyskinesia in the mentally retarded: comparison of prevalence, risk factors and topography with a schizophrenic population.
    Cohen S; Khan A; Zheng Y; Chiles J
    Acta Psychiatr Scand; 1991 Mar; 83(3):234-7. PubMed ID: 1674398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A survey of tardive dyskinesia in psychiatric inpatients in Japan.
    Koshino Y; Madokoro S; Ito T; Horie T; Mukai M; Isaki K
    Clin Neuropharmacol; 1992 Feb; 15(1):34-43. PubMed ID: 1349507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing epidemiology of tardive dyskinesia: an overview.
    Jeste DV; Wyatt RJ
    Am J Psychiatry; 1981 Mar; 138(3):297-309. PubMed ID: 6110344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
    Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tardive dyskinesia: managing a common neuroleptic side effect.
    Jeste DV; Krull AJ; Kilbourn K
    Geriatrics; 1990 Dec; 45(12):49-54. PubMed ID: 1979304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence of tardive dyskinesia in geropsychiatric outpatients.
    Chacko RC; Root L; Marmion J; Molinari V; Adams GL
    J Clin Psychiatry; 1985 Feb; 46(2):55-7. PubMed ID: 2857168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.